GLP1Base
Menu

Ingelheim am Rhein, Germany

Boehringer Ingelheim

German pharmaceutical company developing survodutide, an investigational once-weekly glucagon/GLP-1 dual agonist for obesity and liver disease, under a licence from Zealand Pharma. Survodutide was not approved by any regulator we could verify as of 2026-09-29.

Last verified 2026-09-29 · how we verify

Company website
SYNCHRONIZE-1 phase 3 result
The phase 3 SYNCHRONIZE-1 trial of survodutide in 725 adults with obesity or overweight and without diabetes was published in the New England Journal of Medicine (online on 7 June 2026; issue dated 20 August 2026) and funded by Boehringer Ingelheim. At week 76, mean weight change (treatment-regimen estimand) was -12.2% and -13.0% in the two survodutide groups versus -5.4% with placebo. Gastrointestinal events were the most common side effects.[src]
Rights to survodutide
Zealand Pharma stated on 28 April 2026 that survodutide is licensed to Boehringer Ingelheim, which is solely responsible for its global development and commercialisation. In the same announcement Zealand reported average weight loss of up to 16.6% at 76 weeks versus 3.2% with placebo, using the efficacy estimand (which estimates the effect if people stay on treatment as planned).[src]
Phase 3 liver disease trial
ClinicalTrials.gov lists Boehringer Ingelheim as sponsor of LIVERAGE, a Phase 3 placebo-controlled trial of survodutide in adults with MASH (fatty liver disease with inflammation) and moderate or advanced liver fibrosis, with a planned 1,800 participants. Survodutide is investigational.[src]

Molecules

Key events

  1. 2026-06-07

    Survodutide phase 3 SYNCHRONIZE-1 results published in NEJM

    In SYNCHRONIZE-1, 725 adults with obesity or overweight lost an average of 12.2% or 13.0% of body weight at week 76 on two survodutide dose levels, versus 5.4% on placebo (treatment-regimen estimand). Survodutide, a glucagon and GLP-1 receptor agonist, was investigational when the results were published; the trial was funded by Boehringer Ingelheim.[src]

Sources (4)

  1. 01Survodutide Once Weekly for the Treatment of Adults with ObesityN Engl J Med (via PubMed) · 2026-08-20 · accessed 2026-09-29
  2. 02Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6%Zealand Pharma (via GlobeNewswire) · 2026-04-28 · accessed 2026-09-29
  3. 03LIVERAGE: A Study to Test Whether Survodutide Helps People With NASH/MASH Who Have Moderate or Advanced Liver Fibrosis, NCT06632444ClinicalTrials.gov (U.S. National Library of Medicine) · 2024-10-09 · accessed 2026-09-29
  4. 04Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1)The New England Journal of Medicine · 2026-06-07 · accessed 2026-09-29